847560-50-3

Usage

Uses

Used in Pharmaceutical Synthesis:
4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde serves as a crucial intermediate in the pharmaceutical industry, where it is used as a building block for the synthesis of complex organic molecules with potential therapeutic applications. Its structural features facilitate the development of new drugs with improved efficacy and selectivity.
Used in Agrochemical Development:
In the agrochemical sector, 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde is utilized as a precursor in the synthesis of novel compounds designed to protect crops from pests and diseases. Its unique structure allows for the creation of agrochemicals with enhanced activity and reduced environmental impact.
Used in Fine Chemicals Production:
4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde is also employed in the production of fine chemicals, which are high-purity chemicals used in various industries, including fragrances, flavors, and specialty materials. Its versatility in synthesis contributes to the creation of a wide range of high-value products.
Used in Suzuki-Miyaura Cross-Coupling Reactions:
A significant application of 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde lies in its role as a reagent in Suzuki-Miyaura cross-coupling reactions. These reactions are pivotal in the synthesis of biaryl compounds, which are prevalent structural motifs in pharmaceuticals, natural products, and materials science. The boron-containing group in 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde enhances its reactivity and selectivity in such cross-coupling processes.
Used in the Preparation of Functionalized Derivatives:
The presence of the aldehyde group in 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde allows for its use in the preparation of various functionalized derivatives. These derivatives can be employed across different industries for applications such as the synthesis of polymers, dyes, and other specialty chemicals, where their unique properties can be harnessed for specific technical or commercial advantages.

Upstream product

• 104-87-0 4-methyl-benzaldehyde 
• 36276-24-1 3-bromo-4-methyl-benzaldehyde 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 942921-47-3 4-bromo-2-(3-formyl-6-methyl-phenyl)-1-phenylsulfonyl-1Hpyrrolo[2,3-b]pyridine 

Relevant academic research and scientific papers

SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY

The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

OLEFIN SUBSTITUTED OXINDOLES HAVING AMPK ACTIVITY

The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

Discovery of GSK1070916, a potent and selective inhibitor of aurora B/C kinase

The Aurora kinases play critical roles in the regulation of mitosis and are frequently overexpressed or amplified in human tumors. Selective inhibitors may provide a new therapy for the treatment of tumors with Aurora kinase amplification. Herein we describe our lead optimization efforts within a 7-azaindole-based series culminating in the identification of GSK1070916 (17k). Key to the advancement of the series was the introduction of a 2-aryl group containing a basic amine onto the azaindole leading to significantly improved cellular activity. Compound 17k is a potent and selective ATP-competitive inhibitor of Aurora B and C with Ki* values of 0.38 ± 0.29 and 1.5 ± 0.4 nM, respectively, and is >250-fold selective over Aurora A. Biochemical characterization revealed that compound 17k has an extremely slow dissociation half-life from Aurora B (>480 min), distinguishing it from clinical compounds 1 and 2. In vitro treatment of A549 human lung cancer cells with compound 17k results in a potent antiproliferative effect (EC50 = 7 nM). Intraperitoneal administration of 17k in mice bearing human tumor xenografts leads to inhibition of histone H3 phosphorylation at serine 10 in human colon cancer (Colo205) and tumor regression in human leukemia (HL-60). Compound 17k is being progressed to human clinical trials.

AZAINDOLE INHIBITORS OF AURORA KINASES

The present invention relates to a compound represented by Formula (I): and pharmaceutically acceptable salts. Compounds of the present invention inhibit Aurora kinase, making them especially suitable for the treatment of a number of diseases, including s

PYRIMIDOTHIOPHENE COMPOUNDS

Compounds of formula (1) are inhibitors of HSP90 activity in vitroor in vivo, and of use in the treatment of inter alia, cancer: wherein R2 is a group of formula -(Ar1)m-(Alk1)P-(Z)r-(Alk2)